1. MorphiDex® (MS:DM) Double-Blind, Multiple-Dose Studies In Chronic Pain Patients 
Nathaniel P Katz, MD 
Journal of Pain and Symptom Management 
Volume 19, Issue 1, Pages (January 2000)
DOI: /S (99)

2. Fig. 1
Mean percentage of days patients experienced satisfactory pain relief during the crossover study. The shaded bar represents the MS:DM group; the open bar represents the MS group. Overall, there was no statistical difference in pain relief between the MS:DM group and MS group at any time point
Journal of Pain and Symptom Management  , 37-41DOI: ( /S (99) )

3. Fig. 2
Average increase or decrease in morphine daily dose used to achieve satisfactory pain control over the initial 2 wk of the crossover study. The decrease from baseline in the MS:DM group was significant (P < 0.001). The increase from baseline in the MS group was significant (P = 0.007). The MS:DM group and the MS group were significantly different from each other (P < 0.001)
Journal of Pain and Symptom Management  , 37-41DOI: ( /S (99) )

4. Fig. 3
Mean percentage of days patients experienced satisfactory pain relief during the run-in phase and during week 1, week 2, week 3, and week 4 of the parallel study. Shaded bars represent the MS:DM group; open bars represent the MS group. Overall, there was no statistical difference between the MS:DM group and the MS group at any time point
Journal of Pain and Symptom Management  , 37-41DOI: ( /S (99) )

5. Fig. 4
Mean daily morphine dose (mg) during the run-in period (open bars) and after 4 wk (shaded bars) in patients randomized to receive MS or MS:DM. The change from the run-in period to the end of the 4-wk period measured at 16 mg in the MS group versus 1.6 mg in the MS:DM group, and was significantly different (P = 0.025)
Journal of Pain and Symptom Management  , 37-41DOI: ( /S (99) )